ABSTRACT
A trial has been conducted of recombinant alpha 2-interferon (reaferon) used in 32 patients with Ph'[correction of Rh']-positive chronic myeloid leukemia (CML). A chronic stage was in 3, transient in 3 and blast in 1 patients. 25 CML patients were newly diagnosed. The treatment lasted from 2 months to 3 years. Clinicohematological remission was confirmed conventionally and by the degree of Ph'-positive clone reduction. An attempt is made to clarify the mechanism underlying the resistance to reaferon basing on the immunological data (detection of antireaferon neutralizing antibodies). The authors propose a combined treatment (myelosan plus reaferon) of CML which has obvious advantages over myelosan monotherapy.
Subject(s)
Blast Crisis/therapy , Interferon Type I/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Adolescent , Adult , Aged , Blast Crisis/blood , Child , Chronic Disease , Drug Evaluation , Female , Humans , Interferon Type I/adverse effects , Interferon Type I/pharmacokinetics , Interferon alpha-2 , Interferon-alpha , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Male , Middle Aged , Recombinant Proteins , Remission InductionABSTRACT
The effects of a synthetic prostaglandin E1 (PGE1) analog on colony-forming activity in agar cultures of peripheral blood and bone marrow was studied in 28 patients with chronic myeloid leukemia and 9 hematologically healthy subjects. Addition of PGE1 to normal bone marrow culture was followed by a significant drop in the number of colonies per dish in 8 out of the 9 subjects. In leukemic patients, the effect was bizarre. It proved to be in correlation with survival thus suggesting that the effect of PGE1 on colony-forming activity of granulocyte-macrophage precursors be used in predicting survival in patients with chronic myeloid leukemia.
Subject(s)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality , Alprostadil/pharmacology , Blood Cells/drug effects , Bone Marrow/drug effects , Bone Marrow Cells , Colony-Forming Units Assay , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Prognosis , Tumor Cells, Cultured/drug effects , Tumor Stem Cell AssayABSTRACT
The described basophilic variant of CML in blastic crisis was characterized by a distinct hyperhistaminemia, a moderate hypocoagulation and an insufficiently effective cytostatic therapy. Cell kinetic was characterized by a marked diminution of the whole marketing index (with H3-thymidine) of blasts and immature basophils with simultaneous prolongation of the generation time in comparison to myeloblasts at the chronic stage of the CML. Aneuploid cell clones prevailed in the bone-marrow.
Subject(s)
Basophils , Leukemia, Myeloid/blood , Adult , Blood Coagulation Disorders/complications , Bone Marrow Cells , Clone Cells , DNA/analysis , Genetic Variation , Histamine Release , Humans , Karyotyping , Leukemia, Myeloid/complications , Male , Ploidies , Time FactorsABSTRACT
The authors report the results of the clinical, cytochemical, cytogenetic and kinetic studies (3H-thymidine autoradiography and scanning integrating cytospectrophotometry of DNA) in a male patient with chronic myeloleukemia with blast infiltration of the lymph nodes. Analysis of the karyotype and kinetic aspects of leukemic cells obtained from the blood, bone marrow, spleen and hyperplastic lymph nodes was performed over time at different disease periods. Based on the data obtained the authors suggest that aneuploid blasts may maturate before segmented granulocytes. The probability of the medullary origin of aneuploid clones is discussed.
